Going off on Parkison’s ‘off’ time

Adamas presents new post-hoc Phase 3 data analysis for Gocovri in Parkinson’s disease at the 2020 AAN Science Highlights Platform

DDNews Staff
EMERYVILLE, Calif.—Adamas Pharmaceuticals Inc. a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, in mid-July announced its presentation of a new post-hoc pivotal trial data analysis at the American Academy of Neurology (AAN) Science Highlights Platform showing Gocovri decreasing dyskinesia and Parkinson’s disease (PD) “off” time (a period experienced for many Parkinson’s patients when their symptoms return, often because medication isn’t working optimally) for people with PD.
 
Gocovri (amantadine) extended-release capsules are indicated for the treatment of dyskinesia in people with Parkinson’s disease receiving levodopa-based therapy.
 
In this pooled retrospective data analysis, the subset of patients who experienced more than 2.5 hours of off time and at least an hour of troublesome dyskinesia a day (101 patients out of total 198 enrolled in clinical trials) were evaluated which showed an improvement of 3.4 hours per day in good “on” time on Gocovri, compared to placebo. This improvement in good on time was due to a reduction in the number of hours spent in off as well as the hours spent “on” with troublesome dyskinesia. In addition to increasing good on time, patient-reported assessments showed Gocovri demonstrated significant improvements in the impact of their symptoms on daily activities and provided more continuous on time without interruptions from off time and dyskinesia episodes.
 
“This presentation aims to provide additional insights on the effect of Gocovri in reducing off time for patients with Parkinson’s disease,” said Dr. Robert A. Hauser, director of the USF Parkinson’s Disease and Movement Disorders Center Parkinson Foundation Center of Excellence and lead author of the presentation. “For clinicians seeking to improve management of ‘off’ and dyskinesia for patients without adjusting levodopa doses, these results suggest Gocovri could be an important treatment option.”
 
“It is our hope at Adamas that patients will not have to make the difficult decision between reducing off time or troublesome dyskinesia,” said Dr. Jean Hubble vice president of medical affairs at Adamas. “I am encouraged these results show Gocovri can lead to increased good on time, giving patients the opportunity to spend time with family and friends with fewer disruptions and more sustained good on time.”

DDNews Staff

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022